CJC-1295 Ipamorelin Research: Two Receptors, One Pulse, and the Honest Edge of the Evidence

Before the details

Here is the CJC-1295 Ipamorelin research in plain terms. Growth hormone (GH) is the body's overnight signal to repair and grow. A gland in the brain releases it on two cues: GHRH, an accelerator, and ghrelin, a second, different accelerator. CJC-1295 is a long-lasting copy of the GHRH cue. Ipamorelin is a clean copy of the ghrelin cue. Pressed at the same time, the two raise GH more than either alone — a real effect, shown for the separate peptides and for related GHRH-plus-GHRP pairs.

What the studies measure precisely: how high GH and IGF-1 climb, for how long, and how cleanly. What they cannot tell us: how this exact mixed pair behaves in people, because that experiment has not been run. The sections below give the real numbers, name the species and route every time, and mark the seam where measured fact becomes reasonable inference.

The dual-receptor mechanism

CJC-1295 binds the GHRH receptor — a class-B G-protein-coupled receptor on the pituitary's somatotroph cells (the cells that make GH) — raising the second messenger cAMP through Gs, which drives GH synthesis and release. Ipamorelin binds GHS-R1a, the ghrelin receptor, on those same cells, raising intracellular calcium through a separate Gq pathway. Two doors, two keys, one room.

Because the arms act through independent, complementary routes, co-stimulation produces a GH pulse larger than the sum of its parts. The mechanistic case was built in stages: Bowers showed in 1990 that submaximal GHRP combined with GHRH released GH synergistically in normal men ^[3]; Cunha and Mayo showed in 2002 that co-activating the cloned ghrelin and GHRH receptors in transfected cells produced roughly twice the cAMP of GHRH alone, suggesting direct receptor cross-talk ^[4]. The ghrelin arm also works partly by opposing somatostatin, the brake on GH — pulling the brake off while pressing the accelerator.

The CJC-1295 numbers

The pharmacodynamics of CJC-1295 are the best-quantified part of the pair. In healthy adults aged 21 to 61, a single subcutaneous dose of CJC-1295 with DAC (studied at 30 or 60 µg/kg in ascending single and multiple doses) raised mean plasma GH 2- to 10-fold for six days or more, and IGF-1 1.5- to 3-fold for nine to eleven days; after multiple doses, IGF-1 remained above baseline for as long as 28 days ^[1]. That multi-day profile is the signature of the DAC form.

The chemistry behind it is specific. CJC-1295 carries an N-epsilon-maleimidopropionamide-lysine — a reactive handle — that covalently bonds to the Cys34 thiol of serum albumin. In rats, the bioconjugate produced roughly a 4-fold increase in GH area-under-the-curve over two hours versus plain hGRF(1-29), with albumin-bound peptide still detectable in plasma beyond 72 hours ^[5]. Engineered amino-acid substitutions additionally resist DPP-IV, the enzyme that shreds native GHRH within minutes.

The ipamorelin numbers

Ipamorelin's defining result is selectivity. It was the first growth hormone secretagogue shown to release GH without dragging the stress axis along: unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol above GHRH-stimulated levels even at doses more than 200 times the ED50 for GH release, while still matching GHRP-6's GH efficacy in swine (where its ED50 was 2.3 nmol/kg) ^[2]. That clean profile — GH up, stress hormones flat — is why ipamorelin became the GHRP of choice for the pairing.

A 2026 orthopaedic review placed ipamorelin among the GH secretagogues that activate IGF-1 signalling and satellite-cell (muscle-repair) pathways, but was blunt that the human evidence is missing: it identified a current lack of clinical trials and emphasized that safety and efficacy for ipamorelin remain unvalidated in human orthopaedic contexts, with most evidence confined to preclinical models ^[11].

Ipamorelin vs sermorelin

Ipamorelin vs sermorelin is a comparison of two different jobs, not two grades of the same thing. Sermorelin is a GHRH analogue — it pushes the same accelerator as the CJC-1295 arm, the GHRH receptor, with a short native-like action. Ipamorelin is a GHRP — it pushes the other accelerator, the ghrelin receptor ^[2]. They are complementary rather than competing: the whole synergy rationale, from Bowers onward, is that a GHRH and a GHRP together release more GH than either class alone ^[3]. So 'which is better' is the wrong axis; in mechanism terms they are two halves that a stack is built to combine, and CJC-1295 (a longer-acting GHRH analogue) is closer to sermorelin's role than to ipamorelin's.

Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin again contrasts a GHRP with a GHRH analogue. Tesamorelin is a stabilized GHRH analogue, and it carries the best high-quality efficacy data in this neighbourhood: a 2026 meta-analysis of five randomized controlled trials found significant reductions in visceral adipose tissue (mean difference −27.71 cm²) and hepatic fat (−4.28%), increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events or glucose perturbation ^[7]. Ipamorelin has no comparable controlled human dataset — its evidence is largely preclinical ^[11]. So the tesamorelin record is the read-across context for the GHRH arm of the combination, not a measure of ipamorelin or of the mixed pair, which remains unstudied as a fixed blend.

Where the evidence stops

Every number above belongs to a single component or a related-peptide pairing. There is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295/ipamorelin combination itself. CJC-1295 with DAC reached Phase 2 with ConjuChem before development was discontinued (a Phase 2 program ended after an adverse event in one subject, reported as unrelated to the established mechanism); ipamorelin was investigated, including a postoperative-ileus program, but was never advanced to approval. The combination's case is assembled from the parts: each compound's own literature, plus the general GHRH-plus-GHRP synergy evidence ^[3][4]. The class's best safety synthesis is favorable in the short term, names mild glucose elevation as the consistent metabolic signal, and leaves long-term cancer-incidence and mortality questions open ^[6]. That is the edge of what is known, stated plainly.